Pre-made Canakinumab benchmark antibody ( Whole mAb, anti-IL1B therapeutic antibody, Anti-IL-1/IL1-BETA/IL1F2/IL1beta Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Canakinumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Canakinumab (INN), sold under the brand name Ilaris is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still’s disease, including adult-onset Still’s disease (AOSD). It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
| Products Name (INN Index) | Pre-Made Canakinumab biosimilar, Whole mAb, Anti-IL1B Antibody: Anti-IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody |
|---|---|
| INN Name | Canakinumab |
| Target | IL1B |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 4g5z:HL/5bvj:HG:FE:BA:DC/4g6j:HL/5bvp:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2007 |
| Year Recommended | 2008 |
| Companies | Charite – Universitatsmedizin Berlin,Novartis,Triemli hospital,University Hospital Tubingen,University Hospital Zurich |
| Conditions Approved | Adult-onset Still's disease,Cryopyrin-associated periodic syndromes,Familial autosomal dominant periodic fever,Familial Mediterranean fever,Gouty arthritis,Juvenile rheumatoid arthritis,Peroxisomal d |
| Conditions Active | Cardiovascular disorders,Behcet's syndrome,Non-small cell lung cancer,Abdominal aortic aneurysm,Atherosclerosis,Malignant melanoma,Osteoarthritis,Peripheral arterial occlusive disorders,Pulmonary sar |
| Conditions Discontinued | Chronic obstructive pulmonary disease,Asthma,Diabetic retinopathy,Polymyalgia rheumatica,Rheumatoid arthritis,Type 1 diabetes mellitus,Type 2 diabetes mellitus |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | IL1B |
| Package |
